Logo

Eisai Announces New Investigational Data Evaluating TKI-mTOR Inhibitor Regimen LENVIMA? (lenvatinib) Plus Everolimus in Advanced Renal Cell Carcinoma (RCC) at IKCS 2020

Share this
Eisai Announces New Investigational Data Evaluating TKI-mTOR Inhibitor Regimen LENVIMA? (lenvatinib) Plus Everolimus in Advanced Renal Cell Carcinoma (RCC) at IKCS 2020

Eisai Announces New Investigational Data Evaluating TKI-mTOR Inhibitor Regimen LENVIMA? (lenvatinib) Plus Everolimus in Advanced Renal Cell Carcinoma (RCC) at IKCS 2020

WOODCLIFF LAKE, N.J.,?Nov. 7, 2020?/PRNewswire/ --?Eisai announced results from Study 218, a Phase 2 trial comparing the safety and efficacy of two different starting doses (18 mg versus 14 mg once daily) of LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus everolimus (5 mg once daily) in patients with clear-cell renal cell carcinoma (RCC) following treatment with an anti-angiogenic therapy, with prior anti-PD-1/PD-L1 therapy permitted, during an oral presentation at the International Kidney Cancer Symposium (IKCS) 2020. Results indicate that the lower starting dose (14 mg) of LENVIMA did not meet the threshold for non-inferiority compared to the FDA-approved starting dose (18 mg).
"With the influx of options for patients in the advanced RCC space, it is important that we continue to evaluate data in order to determine the most effective course of action that may help maximize therapeutic effects while managing tolerability for patients," said?Sumanta Pal, MD, Co-director of the Kidney Cancer Program and clinical professor, Department of Medical Oncology & Therapeutics at City of Hope Comprehensive Cancer Center,?Duarte, Calif., and lead investigator of the study. "The results from Study 218 show the potential benefit of LENVIMA plus everolimus in patients with advanced RCC, while providing a similar safety profile seen in previous studies."
The objective of this randomized, open-label, Phase 2 trial (NCT03173560) was to assess whether a starting dose of LENVIMA 14 mg once daily plus everolimus 5 mg once daily would provide similar efficacy with an improved safety profile compared to the FDA-approved dosage of LENVIMA 18 mg once daily plus everolimus 5 mg once daily. The primary efficacy endpoint was noninferiority of LENVIMA 14 mg versus 18 mg for objective response rate (ORR) at Week 24 (ORRWK24) (odds ratio: >0.76;?P-value: = 0.045) based on investigator assessment per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. The primary safety endpoint was superiority of the proportion of patients with intolerable Grade 2 or any = Grade 3 treatment-emergent adverse events (TEAEs) within 24 weeks after randomization in the 14 mg versus 18 mg treatment arms. Some key secondary endpoints included overall ORR, progression-free survival (PFS) overall survival (OS) and safety. The study enrolled 343 patients. In the primary efficacy analysis (n=311 patients), ORR at week 24 for patients treated with LENVIMA at the lower starting dose (14 mg) was not non-inferior to ORR at week 24 for patients treated with the approved starting dose (18 mg) (odds ratioORRWK24: 0.88 [90%?CI: 0.59-1.32];?P-value: 0.2676).?ORR at Week 24 for patients starting with 14 mg and 18 mg was 32.1% (95% CI: 24.7-39.4) and 34.8% (95% CI: 27.3-42.3), respectively. In the primary safety analysis (n=309), the occurrence of intolerable Grade 2 or any = Grade 3 TEAEs was similar between the 14 mg and 18 mg treatment arms: 82.8% vs. 79.6% (P-value: 0.4763), respectively. The 18 mg starting dose of LENVIMA plus everolimus 5 mg demonstrated a similar safety profile as seen in a previous Phase 2 trial (Study 205). In the full safety analysis set (all patients who were randomized and received at least one dose of study drug, n=341), TEAEs led to:
  • discontinuation in 32.4% vs. 26.8% of patients who received LENVIMA 14 mg and 18 mg, respectively;
  • dose interruption in 74.6% vs. 83.3% of patients who received LENVIMA 14 mg and 18 mg, respectively; and
  • dose reductions in 67.6% vs. 69.6% of patients who received LENVIMA 14 mg and 18 mg, respectively.
Overall ORR (based on the primary efficacy analysis set of n=311) for patients starting with 14 mg and 18 mg of LENVIMA was 34.6% (95% CI: 27.1-42.1) and 40.6% (95% CI: 32.9-48.4), respectively (odds ratio: 0.77 [90%?CI: 0.52-1.14]).?Median PFS and median OS indicated a numerical benefit for patients treated with LENVIMA at 18 mg compared to LENVIMA at 14 mg:
  • Median PFS was 11.1 months (95% CI: 9.0-12.9) for patients treated with 14 mg vs. 14.7 months (95% CI: 11.1-20.3) for patients treated with 18 mg; and
  • Median OS was 27.0 months (95% CI: 18.3-NE) for patients treated with 14 mg vs. NE (95% CI: 23.8-NE) for patients treated with 18 mg.
Some of the most common any-grade TEAEs (= 20%) across the 14 mg and 18 mg treatment arms included diarrhea (68.2% vs. 72.0%), hypertension (30.1% vs. 35.7%), proteinuria (22.5% vs. 35.7%), decreased appetite (35.3% vs. 34.5%), and nausea (30.6% vs. 31.0%). Serious TEAEs (= 2%) occurred in 49.1% of patients who received LENVIMA 14 mg and 48.8% of patients who received LENVIMA 18 mg. "This research demonstrates our commitment to advancing our understanding of our oncology compounds and generates key insights for the medical community to help inform treatment decisions around dosing," said?Dr.?Corina Dutcus, Vice President of Clinical Research for the Oncology Business Group at Eisai. "This study, in which 343 patients received LENVIMA plus everolimus, helps to contribute to the growing body of evidence supporting the role of this TKI-mTOR combination in the advanced RCC treatment paradigm." Study 218 was conducted as a post-marketing commitment to the U.S. Food and Drug Administration and the European Medicines Agency (EMA) following priority review designation (in the U.S.) and approval of LENVIMA plus everolimus for the treatment of patients with advanced RCC who were previously treated with an anti-angiogenic therapy. LENVIMA is marketed as KISPLYX??in the European Union and?Switzerland?for this indication. In?March 2018, Eisai and Merck (known as MSD outside?the United States?and?Canada), through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA. This release discusses investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval. About Renal Cell Carcinoma (RCC) Worldwide, it is estimated there were more than 403,000 new cases of kidney cancer diagnosed and more than 175,000 deaths from the disease in 2018. In the U.S. alone, it is estimated there will be nearly 74,000 new cases of kidney cancer diagnosed and almost 15,000 deaths from the disease in 2020. Renal cell carcinoma is by far the most common type of kidney cancer; about nine out of 10 kidney cancers are RCCs.?Renal cell carcinoma is about twice as common in men as in women.?Most cases of RCC are discovered incidentally during imaging tests for other abdominal diseases. Approximately 30% of patients with RCC will have metastatic disease at diagnosis, and as many as 40% will develop metastases after primary surgical treatment for localized RCC. Survival is highly dependent on the stage at diagnosis, and with a 5-year survival rate of 12% for metastatic disease, the prognosis for these patients is poor. About LENVIMA??(lenvatinib) Capsules LENVIMA?is indicated:
  • For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC)
  • In combination with everolimus, for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy
  • For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)
  • In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy, and are not candidates for curative surgery or radiation. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial
LENVIMA, discovered and developed by Eisai, is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1-4, the platelet derived growth factor receptor alpha (PDGFRa), KIT, and RET. In syngeneic mouse tumor models, lenvatinib decreased tumor-associated macrophages, increased activated cytotoxic T cells, and demonstrated greater antitumor activity in combination with an anti-PD-1 monoclonal antibody compared to either treatment alone. The combination of LENVIMA and everolimus showed increased anti-angiogenic and anti-tumor activity as demonstrated by decreased human endothelial cell proliferation, tube formation, and VEGF signaling in vitro and tumor volume in mouse xenograft models of human renal cell cancer greater than each drug alone. Important Safety Information Warnings and Precautions Hypertension.?In DTC, hypertension occurred in 73% of patients on LENVIMA (44% grade 3-4). In RCC, hypertension occurred in 42% of patients on LENVIMA + everolimus (13% grade 3). Systolic blood pressure =160 mmHg occurred in 29% of patients, and 21% had diastolic blood pressure =100 mmHg. In HCC, hypertension occurred in 45% of LENVIMA-treated patients (24% grade 3). Grade 4 hypertension was not reported in HCC. Serious complications of poorly controlled hypertension have been reported. Control blood pressure prior to initiation. Monitor blood pressure after 1 week, then every 2 weeks for the first 2 months, and then at least monthly thereafter during treatment. Withhold and resume at reduced dose when hypertension is controlled or permanently discontinue based on severity. Cardiac Dysfunction.?Serious and fatal cardiac dysfunction can occur with LENVIMA. Across clinical trials in 799 patients with DTC, RCC, and HCC, grade 3 or higher cardiac dysfunction occurred in 3% of LENVIMA treated patients. Monitor for clinical symptoms or signs of cardiac dysfunction. Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity Arterial Thromboembolic Events.?Among patients receiving LENVIMA or LENVIMA + everolimus, arterial thromboembolic events of any severity occurred in 2% of patients in RCC and HCC and 5% in DTC. Grade 3-5 arterial thromboembolic events ranged from 2% to 3% across all clinical trials. Permanently discontinue following an arterial thrombotic event. The safety of resuming after an arterial thromboembolic event has not been established and LENVIMA has not been studied in patients who have had an arterial thromboembolic event within the previous 6 months. Hepatotoxicity.?Across clinical studies enrolling 1,327 LENVIMA-treated patients with malignancies other than HCC, serious hepatic adverse reactions occurred in 1.4% of patients. Fatal events, including hepatic failure, acute hepatitis and hepatorenal syndrome, occurred in 0.5% of patients. In HCC, hepatic encephalopathy occurred in 8% of LENVIMA-treated patients (5% grade 3-5). Grade 3-5 hepatic failure occurred in 3% of LENVIMA-treated patients. 2% of patients discontinued LENVIMA due to hepatic encephalopathy and 1% discontinued due to hepatic failure. Monitor liver function prior to initiation, then every 2 weeks for the first 2 months, and at least monthly thereafter during treatment. Monitor patients with HCC closely for signs of hepatic failure, including hepatic encephalopathy. Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity. Renal Failure or Impairment.?Serious including fatal renal failure or impairment can occur with LENVIMA. Renal impairment was reported in 14% and 7% of LENVIMA-treated patients in DTC and HCC, respectively. Grade 3-5 renal failure or impairment occurred in 3% of patients with DTC and 2% of patients with HCC, including 1 fatal event in each study. In RCC, renal impairment or renal failure was reported in 18% of LENVIMA + everolimus?treated patients (10% grade 3). Initiate prompt management of diarrhea or dehydration/hypovolemia. Withhold and resume at reduced dose upon recovery or permanently discontinue for renal failure or impairment based on severity. Proteinuria.?In DTC and HCC, proteinuria was reported in 34% and 26% of LENVIMA-treated patients, respectively. Grade 3 proteinuria occurred in 11% and 6% in DTC and HCC, respectively. In RCC, proteinuria occurred in 31% of patients receiving LENVIMA + everolimus (8% grade 3). Monitor for proteinuria prior to initiation and periodically during treatment. If urine dipstick proteinuria =2+ is detected, obtain a 24-hour urine protein. Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity. Diarrhea.?Of the 737 LENVIMA-treated patients in DTC and HCC, diarrhea occurred in 49% (6% grade 3). In RCC, diarrhea occurred in 81% of LENVIMA + everolimus?treated patients (19% grade 3). Diarrhea was the most frequent cause of dose interruption/reduction, and diarrhea recurred despite dose reduction. Promptly initiate management of diarrhea. Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity. Fistula Formation and Gastrointestinal Perforation.?Of the 799 patients treated with LENVIMA or LENVIMA + everolimus in DTC, RCC, and HCC, fistula or gastrointestinal perforation occurred in 2%. Permanently discontinue in patients who develop gastrointestinal perforation of any severity or grade 3-4 fistula. QT Interval Prolongation.?In DTC, QT/QTc interval prolongation occurred in 9% of LENVIMA-treated patients and QT interval prolongation of >500 ms occurred in 2%. In RCC, QTc interval increases of >60 ms occurred in 11% of patients receiving LENVIMA + everolimus and QTc interval >500 ms occurred in 6%. In HCC, QTc interval increases of >60 ms occurred in 8% of LENVIMA-treated patients and QTc interval >500 ms occurred in 2%. Monitor and correct electrolyte abnormalities at baseline and periodically during treatment. Monitor electrocardiograms in patients with congenital long QT syndrome, congestive heart failure, bradyarrhythmias, or those who are taking drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. Withhold and resume at reduced dose upon recovery based on severity. Hypocalcemia.?In DTC, grade 3-4 hypocalcemia occurred in 9% of LENVIMA-treated patients. In 65% of cases, hypocalcemia improved or resolved following calcium supplementation with or without dose interruption or dose reduction. In RCC, grade 3-4 hypocalcemia occurred in 6% of LENVIMA + everolimus? treated patients. In HCC, grade 3 hypocalcemia occurred in 0.8% of LENVIMA-treated patients. Monitor blood calcium levels at least monthly and replace calcium as necessary during treatment. Withhold and resume at reduced dose upon recovery or permanently discontinue depending on severity. Reversible Posterior Leukoencephalopathy Syndrome.?Across clinical studies of 1,823 patients who received LENVIMA as a single agent, RPLS occurred in 0.3%. Confirm diagnosis of RPLS with MRI. Withhold and resume at reduced dose upon recovery or permanently discontinue depending on severity and persistence of neurologic symptoms. Hemorrhagic Events.?Serious including fatal hemorrhagic events can occur with LENVIMA. In DTC, RCC, and HCC clinical trials, hemorrhagic events, of any grade, occurred in 29% of the 799 patients treated with LENVIMA as a single agent or in combination with everolimus. The most frequently reported hemorrhagic events (all grades and occurring in at least 5% of patients) were epistaxis and hematuria. In DTC, grade 3-5 hemorrhage occurred in 2% of LENVIMA-treated patients, including 1 fatal intracranial hemorrhage among 16 patients who received LENVIMA and had CNS metastases at baseline. In RCC, grade 3-5 hemorrhage occurred in 8% of LENVIMA + everolimus?treated patients, including 1 fatal cerebral hemorrhage. In HCC, grade 3-5 hemorrhage occurred in 5% of LENVIMA-treated patients, including 7 fatal hemorrhagic events. Serious tumor-related bleeds, including fatal hemorrhagic events, occurred in LENVIMA-treated patients in clinical trials and in the postmarketing setting. In postmarketing surveillance, serious and fatal carotid artery hemorrhages were seen more frequently in patients with anaplastic thyroid carcinoma (ATC) than other tumors. Safety and effectiveness of LENVIMA in patients with ATC have not been demonstrated in clinical trials. Consider the risk of severe or fatal hemorrhage associated with tumor invasion or infiltration of major blood vessels (eg, carotid artery). Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity. Impairment of Thyroid Stimulating Hormone Suppression/Thyroid Dysfunction.?LENVIMA impairs exogenous thyroid suppression. In DTC, 88% of patients had baseline thyroid stimulating hormone (TSH) level =0.5 mU/L. In patients with normal TSH at baseline, elevation of TSH level >0.5 mU/L was observed post baseline in 57% of LENVIMA-treated patients. In RCC and HCC, grade 1 or 2 hypothyroidism occurred in 24% of LENVIMA + everolimus?treated patients and 21% of LENVIMA-treated patients, respectively. In patients with normal or low TSH at baseline, elevation of TSH was observed post baseline in 70% of LENVIMA-treated patients in HCC and 60% of LENVIMA + everolimus?treated patients in RCC. Monitor thyroid function prior to initiation and at least monthly during treatment. Treat hypothyroidism according to standard medical practice. Impaired Wound Healing. Impaired wound healing has been reported in patients who received LENVIMA. Withhold LENVIMA for at least 1 week prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of LENVIMA after resolution of wound healing complications has not been established. Embryo-fetal Toxicity.?Based on its mechanism of action and data from animal reproduction studies, LENVIMA can cause fetal harm when administered to pregnant women. In animal reproduction studies, oral administration of lenvatinib during organogenesis at doses below the recommended clinical doses resulted in embryotoxicity, fetotoxicity, and teratogenicity in rats and rabbits. Advise pregnant women of the potential risk to a fetus; and advise females of reproductive potential to use effective contraception during treatment with LENVIMA and for at least 30 days after the last dose. Adverse Reactions In DTC, the most common adverse reactions (=30%) observed in LENVIMA-treated patients were hypertension (73%), fatigue (67%), diarrhea (67%), arthralgia/myalgia (62%), decreased appetite (54%), decreased weight (51%), nausea (47%), stomatitis (41%), headache (38%), vomiting (36%), proteinuria (34%), palmar-plantar erythrodysesthesia syndrome (32%), abdominal pain (31%), and dysphonia (31%). The most common serious adverse reactions (=2%) were pneumonia (4%), hypertension (3%), and dehydration (3%). Adverse reactions led to dose reductions in 68% of LENVIMA-treated patients; 18% discontinued LENVIMA. The most common adverse reactions (=10%) resulting in dose reductions were hypertension (13%), proteinuria (11%), decreased appetite (10%), and diarrhea (10%); the most common adverse reactions (=1%) resulting in discontinuation of LENVIMA were hypertension (1%) and asthenia (1%). In RCC, the most common adverse reactions (=30%) observed in LENVIMA + everolimus?treated patients were diarrhea (81%), fatigue (73%), arthralgia/myalgia (55%), decreased appetite (53%), vomiting (48%), nausea (45%), stomatitis (44%), hypertension (42%), peripheral edema (42%), cough (37%), abdominal pain (37%), dyspnea (35%), rash (35%), decreased weight (34%), hemorrhagic events (32%), and proteinuria (31%). The most common serious adverse reactions (=5%) were renal failure (11%), dehydration (10%), anemia (6%), thrombocytopenia (5%), diarrhea (5%), vomiting (5%), and dyspnea (5%). Adverse reactions led to dose reductions or interruption in 89% of patients. The most common adverse reactions (=5%) resulting in dose reductions were diarrhea (21%), fatigue (8%), thrombocytopenia (6%), vomiting (6%), nausea (5%), and proteinuria (5%). Treatment discontinuation due to an adverse reaction occurred in 29% of patients. In HCC, the most common adverse reactions (=20%) observed in LENVIMA-treated patients were hypertension (45%), fatigue (44%), diarrhea (39%), decreased appetite (34%), arthralgia/myalgia (31%), decreased weight (31%), abdominal pain (30%), palmar-plantar erythrodysesthesia syndrome (27%), proteinuria (26%), dysphonia (24%), hemorrhagic events (23%), hypothyroidism (21%), and nausea (20%). The most common serious adverse reactions (=2%) were hepatic encephalopathy (5%), hepatic failure (3%), ascites (3%), and decreased appetite (2%). Adverse reactions led to dose reductions or interruption in 62% of patients. The most common adverse reactions (=5%) resulting in dose reductions were fatigue (9%), decreased appetite (8%), diarrhea (8%), proteinuria (7%), hypertension (6%), and palmar-plantar erythrodysesthesia syndrome (5%). Treatment discontinuation due to an adverse reaction occurred in 20% of patients. The most common adverse reactions (=1%) resulting in discontinuation of LENVIMA were fatigue (1%), hepatic encephalopathy (2%), hyperbilirubinemia (1%), and hepatic failure (1%). In EC, the most common adverse reactions (=20%) observed in LENVIMA + pembrolizumab - treated patients were fatigue (65%), hypertension (65%), musculoskeletal pain (65%), diarrhea (64%), decreased appetite (52%), hypothyroidism (51%), nausea (48%), stomatitis (43%), vomiting (39%), decreased weight (36%), abdominal pain (33%), headache (33%), constipation (32%), urinary tract infection (31%), dysphonia (29%), hemorrhagic events (28%), hypomagnesemia (27%), palmar-plantar erythrodysesthesia (26%), dyspnea (24%), cough (21%) and rash (21%). Adverse reactions led to dose reduction or interruption in 88% of patients receiving LENVIMA.? The most common adverse reactions (=5%) resulting in dose reduction or interruption of LENVIMA were fatigue (32%), hypertension (26%), diarrhea (18%), nausea (13%), palmar-plantar erythrodysesthesia (13%), vomiting (13%), decreased appetite (12%), musculoskeletal pain (11%), stomatitis (9%), abdominal pain (7%), hemorrhages (7%), renal impairment (6%), decreased weight (6%), rash (5%), headache (5%), increased lipase (5%) and proteinuria (5%). Fatal adverse reactions occurred in 3% of patients receiving LENVIMA + pembrolizumab, including gastrointestinal perforation, RPLS with intraventricular hemorrhage, and intracranial hemorrhage. Serious adverse reactions occurred in 52% of patients receiving LENVIMA + pembrolizumab.? Serious adverse reactions in =3% of patients were hypertension (9%), abdominal pain (6%), musculoskeletal pain (5%), hemorrhage (4%), fatigue (4%), nausea (4%), confusional state (4%), pleural effusion (4%), adrenal insufficiency (3%), colitis (3%), dyspnea (3%), and pyrexia (3%). Permanent discontinuation due to adverse reaction (Grade 1-4) occurred in 21% of patients who received LENVIMA + pembrolizumab.? The most common adverse reactions (>2%) resulting in discontinuation of LENVIMA were?gastrointestinal perforation or fistula (2%),?muscular weakness (2%), and pancreatitis (2%). Use in Specific Populations Because of the potential for serious adverse reactions in breastfed infants, advise women to discontinue breastfeeding during treatment and for at least 1 week after last dose. LENVIMA may impair fertility in males and females of reproductive potential. No dose adjustment is recommended for patients with mild (CLcr 60-89 mL/min) or moderate (CLcr 30-59 mL/min) renal impairment. LENVIMA concentrations may increase in patients with DTC, RCC or EC and severe (CLcr 15-29 mL/min) renal impairment. Reduce the dose for patients with DTC, RCC, or EC and severe renal impairment. There is no recommended dose for patients with HCC and severe renal impairment. LENVIMA has not been studied in patients with end stage renal disease. No dose adjustment is recommended for patients with HCC and mild hepatic impairment (Child-Pugh A). There is no recommended dose for patients with HCC with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment. No dose adjustment is recommended for patients with DTC, RCC, or EC and mild or moderate hepatic impairment. LENVIMA concentrations may increase in patients with DTC, RCC, or EC and severe hepatic impairment. Reduce the dose for patients with DTC, RCC, or EC and severe hepatic impairment. LENVIMA (lenvatinib) is available as 10 mg and 4 mg capsules. Please see Prescribing information for LENVIMA (lenvatinib) at?http://www.lenvima.com/pdfs/prescribing-information.pdf. About the Eisai and Merck Strategic Collaboration
In?March 2018, Eisai and Merck, known as MSD outside?the United States?and?Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA. Under the agreement, the companies will jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with Merck's anti-PD-1 therapy KEYTRUDA. In addition to ongoing clinical studies evaluating the KEYTRUDA plus LENVIMA combination across several different tumor types, the companies have jointly initiated new clinical studies through the LEAP (LEnvatinib And Pembrolizumab) clinical program and are evaluating the combination in 13 different tumor types (endometrial carcinoma, hepatocellular carcinoma, melanoma, non-small cell lung cancer, renal cell carcinoma, squamous cell carcinoma of the head and neck, urothelial cancer, biliary tract cancer, colorectal cancer, gastric cancer, glioblastoma, ovarian cancer, and triple-negative breast cancer) across 19 clinical trials. About Eisai
Eisai is a leading global research and development-based pharmaceutical company headquartered in?Japan, with approximately 10,000 employees worldwide. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our?human health care?(hhc) philosophy. We strive to realize our?hhc?philosophy by delivering innovative products in therapeutic areas with high unmet medical needs, including Oncology and Neurology. In the spirit of?hhc, we take that commitment even further by applying our scientific expertise, clinical capabilities and patient insights to discover and develop innovative solutions that help address society's toughest unmet needs, including neglected tropical diseases and the Sustainable Development Goals. For more information about Eisai, please visit?www.eisai.com?(for global),?us.eisai.com?(for U.S.) or?www.eisai.eu?(for?Europe,?Middle East,?Africa), and connect with us on Twitter (U.S.?and?global) and?LinkedIn?(for U.S.). LENVIMA??is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd. KEYTRUDA??is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,?Kenilworth, N.J., U.S.A. SOURCE Eisai Inc.

Share this article on WhatsApp, LinkedIn and Twitter



Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions